MedPath
HSA Product

SYNTOMETRINE INJECTION

Product approved by Health Sciences Authority (SG)

Basic Information

SYNTOMETRINE INJECTION

INJECTION

Regulatory Information

SIN03588P

July 5, 1989

Prescription Only

Therapeutic

INTRAVENOUS, INTRAMUSCULAR

August 10, 2023

June 3, 2025

XG02AC

Company Information

Panpharma GmbH

PHARMACON PTE LTD

PHARMACON PTE LTD

Active Ingredients

OXYTOCIN

Strength: 5 iu/ml

ERGOMETRINE MALEATE

Strength: 0.5 mg/ml

Detailed Information

Contraindications

**4.3 Contraindications** - Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ - Pregnancy and labour (induction of labour, first stage labour and second stage labour prior to the delivery of the anterior shoulder) due to the risk of uterine hypertonus and associated foetal complications (see section 4.6 Fertility, pregnancy and lactation – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - Primary or secondary uterine inertia - Severe hypertension, pre-eclampsia, eclampsia - Severe cardiac disorders - Severe hepatic or renal impairment - Occlusive vascular disease - Sepsis

Indication Information

**4.1 Therapeutic indications** - Active management of the third stage of labour (in order to facilitate separation of the placenta and to reduce blood loss) - Prevention and treatment of postpartum haemorrhage associated with uterine atony

© Copyright 2025. All Rights Reserved by MedPath